

Chung-Han Lee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/244380/publications.pdf>

Version: 2024-02-01

71
papers

5,417
citations

257357

24
h-index

143943

57
g-index

74
all docs

74
docs citations

74
times ranked

9531
citing authors

#	ARTICLE	IF	CITATIONS
1	Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 1312-1322.	0.8	42
2	Phase II Study of Neoadjuvant Nivolumab in Patients with Locally Advanced Clear Cell Renal Cell Carcinoma Undergoing Nephrectomy. <i>European Urology</i> , 2022, 81, 570-573.	0.9	22
3	Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Nonâ€œClear-Cell Renal Cell Carcinoma and Genomic Correlates. <i>Journal of Clinical Oncology</i> , 2022, 40, 2333-2341.	0.8	72
4	Genomic and Metabolic Hallmarks of SDH- and FH-deficient Renal Cell Carcinomas. <i>European Urology Focus</i> , 2022, 8, 1278-1288.	1.6	11
5	Personalizing First-Line Management of Metastatic Renal Cell Carcinoma: Leveraging Current and Novel Therapeutic Options. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, , 1-9.	2.3	8
6	Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial. <i>Clinical Cancer Research</i> , 2022, 28, 3248-3255.	3.2	24
7	Matched Molecular Profiling of Cell-Free DNA and Tumor Tissue in Patients With Advanced Clear Cell Renal Cell Carcinoma. <i>JCO Precision Oncology</i> , 2022, , .	1.5	3
8	Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinoma. <i>British Journal of Cancer</i> , 2021, 124, 237-246.	2.9	10
9	New approaches to first-line treatment of advanced renal cell carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110347.	1.4	25
10	Comprehensive Molecular Characterization and Response to Therapy in Fumarate Hydrataseâ€œDeficient Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 2910-2919.	3.2	45
11	High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab. <i>Molecular Cancer Research</i> , 2021, 19, 1510-1521.	1.5	20
12	Pretreatment Eosinophil Counts in Patients With Advanced or Metastatic Urothelial Carcinoma Treated With Anti-PD-1/PD-L1 Checkpoint Inhibitors. <i>Journal of Immunotherapy</i> , 2021, 44, 248-253.	1.2	10
13	Lenvatinib plus pembrolizumab in patients with either treatment-naïve or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study. <i>Lancet Oncology</i> , The, 2021, 22, 946-958.	5.1	100
14	Prevalence and Landscape of Actionable Genomic Alterations in Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 5595-5606.	3.2	12
15	Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST) for Lenvatinib plus Everolimus Versus Everolimus Monotherapy in Patients with Advanced Renal Cell Carcinoma. <i>European Urology Open Science</i> , 2021, 31, 1-9.	0.2	2
16	A phase II trial of durvalumab and tremelimumab in metastatic, nonâ€œurothelial carcinoma of the urinary tract. <i>Cancer Medicine</i> , 2021, 10, 1074-1083.	1.3	10
17	Germline Variants Identified in Patients with Early-onset Renal Cell Carcinoma Referred for Germline Genetic Testing. <i>European Urology Oncology</i> , 2021, 4, 993-1000.	2.6	16
18	Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial. <i>Clinical Cancer Research</i> , 2021, 27, 6687-6695.	3.2	25

#	ARTICLE	IF	CITATIONS
19	In silico modeling of combination systemic therapy for advanced renal cell carcinoma. , 2021, 9, e004059.		5
20	Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma. European Urology, 2020, 78, 907-915.	0.9	21
21	Everolimus plus bevacizumab is an effective first-line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial. Cancer, 2020, 126, 5247-5255.	2.0	22
22	DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapy. , 2020, 8, e000230.		37
23	Systemic therapy for advanced clear cell renal cell carcinoma after discontinuation of immune-oncology and VEGF targeted therapy combinations. BMC Urology, 2020, 20, 84.	0.6	12
24	Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors. Journal of Clinical Oncology, 2020, 38, 1154-1163.	0.8	276
25	Mucinous Tubular and Spindle-Cell Carcinoma of the Kidney: Clinical Features, Genomic Profiles, and Treatment Outcomes. Clinical Genitourinary Cancer, 2019, 17, 268-274.e1.	0.9	29
26	Metastatic Chromophobe Renal Cell Carcinoma: Presence or Absence of Sarcomatoid Differentiation Determines Clinical Course and Treatment Outcomes. Clinical Genitourinary Cancer, 2019, 17, e678-e688.	0.9	41
27	The current role for adjuvant and neoadjuvant therapy in renal cell cancer. Current Opinion in Urology, 2019, 29, 636-642.	0.9	12
28	Comprehensive Genomic Analysis of Metastatic Non-“Clear-Cell Renal Cell Carcinoma to Identify Therapeutic Targets. JCO Precision Oncology, 2019, 3, 1-18.	1.5	7
29	Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma. Clinical Genitourinary Cancer, 2019, 17, 1-6.	0.9	60
30	Treatment of Metastatic Prostate Cancer in 2018. JAMA Oncology, 2019, 5, 263.	3.4	16
31	Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nature Genetics, 2019, 51, 202-206.	9.4	2,702
32	Combination therapy for advanced and metastatic kidney cancer. Nature Reviews Urology, 2019, 16, 77-78.	1.9	3
33	Systemic therapy for advanced clear cell renal cell carcinoma (ccRCC) after progression on immune-oncology plus VEGF targeted therapy combinations (IO-VEGF).. Journal of Clinical Oncology, 2019, 37, 4576-4576.	0.8	3
34	Comparative Genomic Profiling of Matched Primary and Metastatic Tumors in Renal Cell Carcinoma. European Urology Focus, 2018, 4, 986-994.	1.6	29
35	<i>ALK</i> Fusions in Renal Cell Carcinoma: Response to Entrectinib. JCO Precision Oncology, 2018, 2, 1-8.	1.5	16
36	Combination VEGFR/immune checkpoint inhibitor therapy: a promising new treatment for renal cell carcinoma. British Journal of Cancer, 2018, 119, 911-912.	2.9	6

#	ARTICLE	IF	CITATIONS
37	Prevalence of Germline Mutations in Cancer Susceptibility Genes in Patients With Advanced Renal Cell Carcinoma. <i>JAMA Oncology</i> , 2018, 4, 1228.	3.4	132
38	Update on Tumor Neoantigens and Their Utility: Why It Is Good to Be Different. <i>Trends in Immunology</i> , 2018, 39, 536-548.	2.9	152
39	Lenvatinib + pembrolizumab in patients with renal cell carcinoma: Updated results.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4560-4560.	0.8	30
40	Everolimus (E) plus bevacizumab (B) is effective first-line treatment for patients (pts) with advanced renal cell carcinoma (RCC) with papillary features (PF): Results from a phase II trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 627-627.	0.8	6
41	Outcomes of metastatic chromophobe renal cell carcinoma (ChRCC) with sarcomatoid features (SF).. <i>Journal of Clinical Oncology</i> , 2018, 36, 678-678.	0.8	0
42	Single-center analysis of 109 patients (pts) with metastatic chromophobe renal cell carcinoma (ChRCC): Differences in outcomes by histologic variant.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4577-4577.	0.8	0
43	The evolution of anti-angiogenic therapy for kidney cancer. <i>Nature Reviews Nephrology</i> , 2017, 13, 69-70.	4.1	19
44	Genomic Characterization of Renal Medullary Carcinoma and Treatment Outcomes. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e987-e994.	0.9	39
45	Tumor Xenografts of Human Clear Cell Renal Cell Carcinoma But Not Corresponding Cell Lines Recapitulate Clinical Response to Sunitinib: Feasibility of Using Biopsy Samples. <i>European Urology Focus</i> , 2017, 3, 590-598.	1.6	31
46	Persistent Severe Hyperlactatemia and Metabolic Derangement in Lethal <i>SDHB</i> -Mutated Metastatic Kidney Cancer: Clinical Challenges and Examples of Extreme Warburg Effect. <i>JCO Precision Oncology</i> , 2017, 1, 1-14.	1.5	9
47	The genomic landscape of metastatic non-clear cell renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 474-474.	0.8	1
48	Discovery and prevalence of cancer-susceptibility germline mutations (Mts) in patients (Pts) with advanced renal cell carcinoma (aRCC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 4524-4524.	0.8	1
49	Immune Checkpoint Therapy in Renal Cell Carcinoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2016, 22, 92-95.	1.0	35
50	Circulating biomarkers and outcome from a randomised phase II trial of sunitinib vs everolimus for patients with metastatic renal cell carcinoma. <i>British Journal of Cancer</i> , 2016, 114, 642-649.	2.9	43
51	Phase II Trial and Correlative Genomic Analysis of Everolimus Plus Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 3846-3853.	0.8	69
52	A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma. <i>Oncologist</i> , 2016, 21, 787-788d.	1.9	84
53	Bevacizumab Monotherapy as Salvage Therapy for Advanced Clear Cell Renal Cell Carcinoma Pretreated With Targeted Drugs. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 56-62.	0.9	7
54	An Integrated Metabolic Atlas of Clear Cell Renal Cell Carcinoma. <i>Cancer Cell</i> , 2016, 29, 104-116.	7.7	531

#	ARTICLE	IF	CITATIONS
55	Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin. <i>Journal of Clinical Investigation</i> , 2016, 126, 3526-3540.	3.9	82
56	Metastasis-associated mutations in clear cell renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, 600-600.	0.8	0
57	Genomic and metabolic characterization of succinate dehydrogenase B deficient renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, e16102-e16102.	0.8	0
58	Medullary renal cell carcinoma (RCC): Genomics and treatment outcomes.. <i>Journal of Clinical Oncology</i> , 2016, 34, 4556-4556.	0.8	3
59	Clinical and genomic alternations predictive of response to sunitinib in patients with advanced renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, e16109-e16109.	0.8	0
60	PBRM1: A Critical Subunit of the SWI/SNF Chromatin Remodeling Complex. , 2015, , 111-151.		1
61	Sunitinib as a paradigm for tyrosine kinase inhibitor development for renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 275-279.	0.8	7
62	Bevacizumab monotherapy as salvage therapy for patients with advanced clear cell renal cell carcinoma pretreated with targeted drugs.. <i>Journal of Clinical Oncology</i> , 2015, 33, 468-468.	0.8	0
63	Novel chromosome copy number changes to predict clinical response to sunitinib in patients with advanced renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, 4552-4552.	0.8	0
64	From molecular understanding to clinical advances. <i>Nature Reviews Urology</i> , 2014, 11, 77-79.	1.9	0
65	MP35-19 SORBITOL AS A NOVEL MECHANISM OF HYPOXIA-INDUCIBLE FACTOR (HIF) PATHWAY ACTIVATION IN CLEAR CELL PAPILLARY RENAL CELL CARCINOMA (CCPRCC). <i>Journal of Urology</i> , 2014, 191, .	0.2	1
66	A systematic review of predictive and prognostic biomarkers for VEGF-targeted therapy in renal cell carcinoma. <i>Cancer Treatment Reviews</i> , 2014, 40, 533-547.	3.4	61
67	Src pathway activation in RCC and the correlation with grade and survival and the development of a rational new target in RCC.. <i>Journal of Clinical Oncology</i> , 2014, 32, 453-453.	0.8	0
68	Global metabolic profiling of clear cell renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2013, 31, 379-379.	0.8	0
69	mTOR Pathway as a Target in Tissue Hypertrophy. <i>Annual Review of Pharmacology and Toxicology</i> , 2007, 47, 443-467.	4.2	162
70	Constitutive mTOR activation in TSC mutants sensitizes cells to energy starvation and genomic damage via p53. <i>EMBO Journal</i> , 2007, 26, 4812-4823.	3.5	153
71	Molecular Characterization of the Tumor Microenvironment in Renal Medullary Carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4